Depemokimab Trial for COPD
Phase 3
960
about 4.2 years
40–80
54 sites in AL, CO, FL +16
About this study
This trial is testing depemokimab, a new medication, as an add-on treatment for adults with moderate to severe COPD and type 2 inflammation. The goal is to see if depemokimab helps improve symptoms in people who don't respond well to standard treatments.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Depemokimab
- 2.Take Placebo
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
monoclonal antibody
Secondary: Annualized Rate of Exacerbations Requiring Emergency Department (ED) Visit or Hospitalization, Change from Baseline in Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease (E-RS: COPD) Total Score at Week 52, Change from Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score at Week 52
Respiratory